InnovAge Holding Corp. heads into the final stretch before its September earnings with a stock that has pulled back quietly but a lending market that tells a remarkably relaxed story.
The clearest tension this week is the gap between price and positioning. INNV fell 1.7% over the week to close at $11.36, and is down 4.1% over the past month. Yet the data underneath the surface looks nothing like a stock under siege — short sellers have been covering aggressively, and the borrow market is about as loose as it gets.
Positioning here is emphatically not a crowded short. Short interest in INNV has dropped 38% over the past month, falling from around 1.4 million shares to under 900,000, equivalent to just 0.65% of the free float. That is a low reading by any measure, and the direction of travel has been one-way. Borrow costs confirm the lack of urgency — the cost to borrow runs at roughly 0.41%, near its lowest level in 30 days, and availability has loosened dramatically. From a tight ~907% in early July, availability has climbed back to over 1,230% — meaning there are more than twelve shares available to borrow for every one currently shorted. The ORTEX short score has also eased steadily, falling from around 40.6 in mid-July to 37.9 by July 30, reflecting the broad reduction in bearish pressure. Options activity reinforces the picture: the put/call ratio is just 0.005, well below its 20-day average of 0.009, pointing to almost no demand for downside protection from options traders. Positioning looks relaxed rather than cautious.
The Street, however, has not been warm on INNV for some time. The most recent active analyst coverage from JP Morgan carries an Underweight rating with a $7.00 price target — last raised from $5.00 in February 2026. That target is roughly 38% below where the stock is trading today at $11.36, a notable gap. The analyst data is now over five months old, so it may not fully reflect the stock's sharp recovery in 2026, but the directional message has been consistently negative. Factor scores offer little additional comfort: the EPS surprise rank sits in the 2nd percentile, meaning InnovAge has a poor track record of beating estimates, and the sector score of 38 suggests it ranks in the lower half of its health care services peers. The ORTEX stock score has been drifting down from a May peak of around 69 to the mid-30s, with quality metrics weakening even as the momentum pillar held up through much of the rally.
Ownership is notably concentrated. TCO Group Holdings controls 83% of the outstanding shares, leaving a very small tradeable float. T. Rowe Price holds another 4.5%, and BlackRock added 149,000 shares in the quarter to June 30. That thin float is worth keeping in mind: with under one million shares short and nearly 20 million shares available to borrow, there is no structural pressure building in the lending market, but it does mean that any shift in sentiment among the few active institutional holders can move the stock disproportionately. Insider activity has leaned consistently toward selling — the President and Chief Legal Officer both sold shares in July at prices near $11.58–$11.87, following similar sales in June around $7.30. Net insider selling over the past 90 days totals roughly $723,000 across 79,000 shares.
Earnings are next due on September 8. The last print in May produced a modest one-day decline of 0.6% but a five-day drop of 7.6% — suggesting any initial relief on the headline number tends to give way to heavier selling once the market digests the details. With the stock trading well above the only active price target on record and insiders trimming into the rally, the September print becomes the natural inflection point to watch.
See the live data behind this article on ORTEX.
Open INNV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
